Academy of Osseointegration elects new president

ARLINGTON HEIGHTS, Ill., U.S.: With 6,000 members in 70 countries around the world, the Academy of Osseointegration (AO) is recognized as one of the premier international associations for professionals interested in implant dentistry. At its recent annual meeting, held on Feb. 28–March 3 in Los Angeles, U.S., the academy appointed its 32nd president, Dr. James C. Taylor from Ottawa, Ontario, Canada. Taylor is AO’s first Canadian president and succeeds Dr. Michael R. Norton from London, U.K.

“I’m honored to have the opportunity to lead our academy in its global role of enabling the development, dissemination and application of knowledge in the domain of implant dentistry, for the well-being of our patients,” said Taylor. “The academy is a grand constellation of interrelated and interdependent elements, perpetually interacting to create a whole that is so much greater than the sum of its parts, which makes AO the world’s premier international academy in the domain of evidence-based and patient-centered care in implant dentistry,” he continued. As part of his presidential address, Taylor also outlined his vision for continuing to move AO forward on its robust strategic course and highlighted his upcoming agenda to foster AO’s message of multidisciplinary and evidence-based patient care in implant dentistry around the world. As part of that vision, Taylor will include a number of outreach and charter chapter initiatives outside North America, as well as regional meetings in North America. Further efforts will be a number of global university programs, as well as AO’s symposiums with the International Association for Dental Research and the FDI World Dental Federation, and the upcoming AO summit in Chicago, U.S. Additionally, the continued partnership between AO and the International Journal of Oral and Maxillofacial Implants will be a focus. “I can say from personal experience that it is rare to assume the presidency of an organization that is already on a sound and successful strategic trajectory. This is a trajectory that I had the privilege of helping to shape and implement during the presidencies of my predecessors, and I plan to stay that course during my presidency,” said Taylor. Taylor’s one-year tenure will culminate at AO’s 2019 annual meeting in Washington, U.S., the theme for which is “Current factors in clinical excellence.”

Tags: Academy of Osseointegration, Canada, dentistry

ADIA and BDIA to sign agreement and strengthen ties

SYDNEY, Australia: Seeking to strengthen existing ties, the Australian Dental Industry Association (ADIA) and the British Dental Industry Association (BDIA) will be signing a cooperative agreement this week. Formalising their informal working relationship of more than 50 years, the new agreement is intended to aid in mutual interests through the sharing of information, working with regulatory offices and promoting their respective members’ products overseas.

“The dental industry in Australia and Britain jointly understand the importance of the role that industry has in supporting dental professionals to deliver optimal oral health. This is achieved through the investment by dental product manufacturers in new and innovative patient treatment options and in this area there is so much that the ADIA and BDIA membership can learn from each other,” said ADIA CEO Troy Williams. ADIA and the BDIA share the policy objective of achieving convergence of the regulations for the market approval of medical devices. According to ADIA, given that in Australia and in Britain the regulatory framework for the approval of medical devices is based upon that of the European Union, the two organisations will benefit owing to a broad understanding and different perspectives on the same regulatory approach. “In the context of Brexit it’s likely that, in many respects, Britain’s dental product regulatory framework may eventually look increasingly like that of Australia. We expect that in the coming years, just like in Australia, the regulations will be based heavily upon those of Europe but with some opportunities for important changes that reflect local conditions,” said BDIA Chief Executive Edmund Proffitt. As part of their collaborative work, both organisations will be hosting national pavilions at key international dental trade shows, such as the International Dental Show in Cologne in Germany and the International Dental Exhibition and Meeting in Singapore. The agreement will be signed at ADX18 Sydney, Australia’s premier dental event and the nation’s largest healthcare trade show.

Tags: Australia, Britain, business, dental industry, Europe

How to deal with biofilm – new approaches in periodontitis, mucositis and peri-implantitis

Non-surgical therapy remains the cornerstone of periodontal treatment. Patient compliance and proper selection and application of adjunctive antimicrobial agents for sustained biofilm control are important elements in achieving successful long-term results in the non-surgical periodontal therapy.

Non-surgical therapy remains the cornerstone of periodontal treatment. Attention to detail, patient compliance and proper selection and application of adjunctive antimicrobial agents for sustained biofilm control are important elements in achieving successful long-term results. Frequent re-evaluation and careful monitoring allows the practitioner the opportunity to intervene early in the disease state, to reverse or arrest the progression of periodontal and peri-implant diseases, with meticulous non-surgical anti-infective therapy. Various treatment modalities, including, antimicrobial therapy, gingival irrigations, and host modulation, may be used as adjunctive treatments in the non-surgical management of periodontal infections. The emerging topic to be addressed in this dental webinar will be peri-implantitis. The non-surgical treatment of this condition has proven quite successful in the case of mucositis. Vice versa, in the case of progressive and irreversible bone loss, the non-surgical solution is not predictable, however, it is recommended as a first therapeutic phase. In some well documented clinical cases, the non-surgical option may have very satisfactory long- term outcomes. In other cases, it can help to significantly prolonging the survival rate of severely compromised implants. The protocol, particularly composite and differentiated, associated with the use of PERISOLV, will be described with clinical images, drawings and videos. Disclaimer 2018 1st of March: Please observe that Dr. Roncati had wrong information. An application for a FDA approval for Perisolv is not filed. Consequently is Perisolv not available in USA yet.
Next page